Analysts at Piper Jaffray, assumed coverage of ContraFect Corporation (NASDAQ:CFRX) with Overweight recommendation, according to their opinion released on July 28. Maxim Group analysts have downgraded their rating of CFRX stock from Buy to Hold in a separate flash note to investors on July 22. Analysts at Maxim Group are sticking to their Buy recommendation. However, on March 15, they lifted target price for these shares to $7 from $8. Analysts at Maxim Group, made their first call for the stock with a Buy rating, according to a research note that dated back to March 15.
Short sellers are betting against ContraFect Corporation (NASDAQ:CFRX). Looking at the sentiment indicator for the CFRX stock we see that the short-interest ratio is at 3.654538 while the average analyst recommendations at 0 suggests selling these shares. Between December 14 and December 31, the total number of shorted shares amounted to 958.56 thousand shares. That was 68.48% more than the total of 568.94 thousand shares in the space of prior two weeks, which means more traders or funds betting that the stock will go down. Average daily volume for ContraFect Corporation at the December 31st settlement plunged to 262,292, as compared to 576,521 at the December 14th report. That brought days to cover to a 265.45% increase from the 1 days to cover recorded at the prior short interest data release.
By watching the trading activity of corporate insiders, it will become easier to get a sense of ContraFect Corporation (NASDAQ:CFRX)’s prospects. The earliest insider trade took place on 12/04/2018. Shanghai Fosun Pharmaceutical parted with a total of 600 thousand shares of company at average share price of $2.04. The total for the sales was set at $1.22 million. After this transaction, the 10% Owner account balance stood at 7.9 million shares. The stock lost -70.1 percent since that insider sale. On 12/04/2018, Fosun Industrial Co., Ltd, 10% Owner, sold 600 thousand shares at a price per share of $2.04. This removed 1.22 million shares from the insider’s fortune and the stock saw a -70.1 percent retreat in value since the news became public. This transaction left 7.9 million shares in the 10% Owner account. On 07/25/2017, Director Blech Isaac performed a purchase transaction worth $19.84 thousand. This purchase at $1.24 each has added 16 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded -50.81 percent decrease since the transaction was reported. The insider now is left with 16 thousand shares remaining in the account. Gilman Steven C, who performs the CEO job, bought 0.8 thousand shares for $0.99 thousand. The acquisition occurred on 07/25/2017 was priced at $1.24 per share. The share price plunged -50.81 percent since the reporting date. Gilman Steven C now left with a stake of 20.8 thousand CFRX stock worth $12.69 thousand after the insider buying.
ContraFect Corporation (CFRX) is expected to jump by 342.62 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $3.5-month high price target. This represents a whopping 473.77 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $2.8, which represents a return potential of 359.02 percent when compared to the closing price of the stock of $0.61 on Friday, January 11. The lowest price target for the stock is $1.5 — slightly more than 145.9 percent from CFRX’s current share price.
The shares are currently floating around the first support level of $0.57. Below this, the next support is placed in the zone of $0.54. Till the time, the CFRX stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 26.94 on daily chart, which may remain a cause for comfort. If the price breaks below $0.54 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $0.64 mark may result into a pull-back move towards $0.67 level.
CFRX shares accumulated 0.05 points or 8.31 percent on Friday to $0.61 with a light trade volume of 5.677 million shares. After opening the session at $0.585, the shares went as high as $0.6366 and as low as $0.57, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $47.24 million and now has 77.45 million shares outstanding. ContraFect Corporation (CFRX) stock has lost -69.8 percent of market value in 21 trading days.
CFRX stock has a trailing 3-year beta of 0.02, offering the possibility of a lower rate of return, but also posing less risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.65 a share in the trailing twelve months. The stock’s value has fallen -60.13 percent year to date (YTD) against a decline of -46.96 percent in 12 month’s time. The company’s shares still trade -79.16 percent away from its 1-year high of $2.93 and 11.29 percent up from 52-week low of $0.55. The average consensus rating on the company is 0, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of ContraFect Corporation (CFRX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry CFRX operates in has an average P/E of 69.71. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 0 on the Price-to-Sales ratio. Compare this with the industry average P/S of 49.51. 0 percent is the gross profit margin for ContraFect Corporation and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.